{
    "clinical_study": {
        "@rank": "154864", 
        "acronym": "SAILOR", 
        "arm_group": [
            {
                "arm_group_label": "Steroid-free low TAC-arm", 
                "arm_group_type": "Experimental", 
                "description": "Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.\nMaintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
            }, 
            {
                "arm_group_label": "Standard low-TAC arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.\nMaintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
            }
        ], 
        "brief_summary": {
            "textblock": "Balancing immunosuppressive treatment in organ transplantation in order to achieve effective\n      prevention of rejection on one side and avoidance of negative side effects on the other side\n      is a major challenge, leading to developing different immunosuppressive protocols.\n      Cornerstones of immunosuppressive treatment such as Corticosteroids (CS) and Calcineurin\n      Inhibitors (CNI) are known to cause an increased incidence of diabetes, cardiovascular\n      morbidity, nephrotoxicity and malignancies.\n\n      The investigators believe that both avoidance of CS and minimization of CNI, while using\n      Anti-ThymocyteGlobuline(ATG) induction (instead of interleucin-2 receptor blockers) and\n      mycofenolate mofetil(MMF) therapeutic drug monitoring is going to reduce negative side\n      effects, without increased rejection frequency in renal transplanted patients."
        }, 
        "brief_title": "Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  First or second single kidney (cadaveric or living donors) transplant recipients.\n\n          -  Considered for a standard immunosuppressive protocol.\n\n          -  Must be capable of giving written informed connect for participation in the study for\n             24 months.\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus or plasma glucose >11,1 at admission.\n\n          -  Receiving steroids at the time of transplantation or likely to need steroids after\n             transplantation.\n\n          -  Multiorgan transplants and/or previously transplanted with any other organ than\n             kidney.\n\n          -  Panel reacting antibodies(PRA) >25% in most recent test or considered to be of high\n             risk for rejection which requires an  enhanced immunosuppression.\n\n          -  Renal transplants from HLA-identical sibling.\n\n          -  Hypersensitivity to, or disability to take immunosuppressive drugs.\n\n          -  Blood group(ABO)-incompatible transplants.\n\n          -  Unlikely to comply with the study requirements.\n\n          -  Transplant from donor positive for HIV, HBsAg, Hepatitis C.\n\n          -  Female of childbearing potential planing/being pregnant or unwilling to use\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083991", 
            "org_study_id": "2012-000451-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "Steroid-free low TAC-arm", 
                "Standard low-TAC arm"
            ], 
            "intervention_name": "Steroid-free low TAC-arm: Thymoglobulin  Standard low-TAC arm: Simulect, prednisolon", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Basiliximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "NODAT", 
            "Renal transplantation", 
            "Corticosteroids avoidance", 
            "CNI minimization"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "email": "per.lindner@vgregion.se", 
                "last_name": "Per Lindn\u00e9r, MD", 
                "phone": "+46705548400"
            }, 
            "contact_backup": {
                "email": "jana.ekberg@vgregion.se", 
                "last_name": "Jana Ekberg", 
                "phone": "+46313421000"
            }, 
            "facility": {
                "address": {
                    "city": "Gothenburg", 
                    "country": "Sweden", 
                    "zip": "41345"
                }, 
                "name": "Transplant Institute, Sahlgrenska University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Controlled Randomized, Open-label, Multi-centre Study Evaluating if a Steroid-free Immunosuppressive Protocol, Based ATG-induction, Low Tacrolimus-dose and Therapeutic Drug Monitoring of Mycophenolate Mofetil, Reduces the Incidence of New Onset Diabetes After Transplantations, in Comparison With Standard Steroid-based Protocol With Low-dose Tacrolimus.", 
        "overall_contact": {
            "email": "per.lindner@vgregion.se", 
            "last_name": "Per Lindn\u00e9r, MD", 
            "phone": "+46705548400"
        }, 
        "overall_official": {
            "affiliation": "Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden", 
            "last_name": "Per Lindn\u00e9r, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT)", 
            "safety_issue": "No", 
            "time_frame": "12 month after transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083991"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cumulative incidence of NODAT", 
                "safety_issue": "No", 
                "time_frame": "3, 6, 24 month after transplantation"
            }, 
            {
                "description": "Freedom from acute rejection, graft and patient survival", 
                "measure": "Composite measure", 
                "safety_issue": "Yes", 
                "time_frame": "12, 24 months"
            }, 
            {
                "description": "Evaluated by measured glomerular filtration rate (mGFR)", 
                "measure": "Renal function", 
                "safety_issue": "No", 
                "time_frame": "12, 24 months"
            }, 
            {
                "description": "Analysed by protocol biopsies, evaluated by the Banff system.", 
                "measure": "Incidence of acute rejection and chronic changes", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Standardized measurement.", 
                "measure": "Incidence of hypertension", 
                "safety_issue": "No", 
                "time_frame": "3, 12, 24 months"
            }, 
            {
                "description": "Number and type of antihypertensive drugs.", 
                "measure": "Antihypertensive treatment", 
                "safety_issue": "No", 
                "time_frame": "3, 12, 24 months"
            }, 
            {
                "description": "Number and type of lipid lowering drugs.", 
                "measure": "Lipid lowering drugs", 
                "safety_issue": "No", 
                "time_frame": "12, 24 months"
            }, 
            {
                "description": "Analysed by biopsies, evaluated by the Banff system, and by donor-specific HLA antibodies", 
                "measure": "Incidence of antibody-mediated rejection", 
                "safety_issue": "No", 
                "time_frame": "12, 24 months"
            }, 
            {
                "description": "Collecting Adverse Events (AE) reports", 
                "measure": "Cumulative frequency of cardiovascular complications and events.", 
                "safety_issue": "Yes", 
                "time_frame": "10 days, 3, 12, 24 months"
            }, 
            {
                "description": "Collecting AE reports", 
                "measure": "Cumulative frequency of malignancy.", 
                "safety_issue": "Yes", 
                "time_frame": "6, 12, 24 months"
            }, 
            {
                "description": "Collecting AE reports", 
                "measure": "Cumulative frequency of infections", 
                "safety_issue": "Yes", 
                "time_frame": "10 days, 3, 6, 12, 24 months"
            }
        ], 
        "source": "Vastra Gotaland Region", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vastra Gotaland Region", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}